These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 17996481)
1. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Margosio B; Rusnati M; Bonezzi K; Cordes BL; Annis DS; Urbinati C; Giavazzi R; Presta M; Ribatti D; Mosher DF; Taraboletti G Int J Biochem Cell Biol; 2008; 40(4):700-9. PubMed ID: 17996481 [TBL] [Abstract][Full Text] [Related]
2. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). Rusnati M; Borsotti P; Moroni E; Foglieni C; Chiodelli P; Carminati L; Pinessi D; Annis DS; Paiardi G; Bugatti A; Gori A; Longhi R; Belotti D; Mosher DF; Colombo G; Taraboletti G Angiogenesis; 2019 Feb; 22(1):133-144. PubMed ID: 30168023 [TBL] [Abstract][Full Text] [Related]
3. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. Colombo G; Margosio B; Ragona L; Neves M; Bonifacio S; Annis DS; Stravalaci M; Tomaselli S; Giavazzi R; Rusnati M; Presta M; Zetta L; Mosher DF; Ribatti D; Gobbi M; Taraboletti G J Biol Chem; 2010 Mar; 285(12):8733-42. PubMed ID: 20056600 [TBL] [Abstract][Full Text] [Related]
4. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Margosio B; Marchetti D; Vergani V; Giavazzi R; Rusnati M; Presta M; Taraboletti G Blood; 2003 Dec; 102(13):4399-406. PubMed ID: 12947001 [TBL] [Abstract][Full Text] [Related]
5. Molecular basis of antiangiogenic thrombospondin-1 type 1 repeat domain interactions with CD36. Klenotic PA; Page RC; Li W; Amick J; Misra S; Silverstein RL Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1655-62. PubMed ID: 23640500 [TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor signaling pathway in endothelial cells is activated by BMPER to promote angiogenesis. Esser JS; Rahner S; Deckler M; Bode C; Patterson C; Moser M Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):358-67. PubMed ID: 25503991 [TBL] [Abstract][Full Text] [Related]
7. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. Guo NH; Krutzsch HC; Inman JK; Shannon CS; Roberts DD J Pept Res; 1997 Sep; 50(3):210-21. PubMed ID: 9309585 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Iruela-Arispe ML; Lombardo M; Krutzsch HC; Lawler J; Roberts DD Circulation; 1999 Sep; 100(13):1423-31. PubMed ID: 10500044 [TBL] [Abstract][Full Text] [Related]
9. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323 [TBL] [Abstract][Full Text] [Related]
11. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Simantov R; Febbraio M; Silverstein RL Matrix Biol; 2005 Feb; 24(1):27-34. PubMed ID: 15748999 [TBL] [Abstract][Full Text] [Related]
12. Expression and characterization of novel thrombospondin 1 type I repeat fusion proteins. Qabar AN; Bullock J; Matej L; Polverini P Biochem J; 2000 Feb; 346 Pt 1(Pt 1):147-53. PubMed ID: 10657251 [TBL] [Abstract][Full Text] [Related]
13. CD36-TSP-HRGP interactions in the regulation of angiogenesis. Silverstein RL; Febbraio M Curr Pharm Des; 2007; 13(35):3559-67. PubMed ID: 18220792 [TBL] [Abstract][Full Text] [Related]
14. Biophysical characterization, including disulfide bond assignments, of the anti-angiogenic type 1 domains of human thrombospondin-1. Huwiler KG; Vestling MM; Annis DS; Mosher DF Biochemistry; 2002 Dec; 41(48):14329-39. PubMed ID: 12450399 [TBL] [Abstract][Full Text] [Related]
15. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. Kanda S; Mochizuki Y; Miyata Y; Kanetake H; Yamamoto N J Natl Cancer Inst; 2002 Sep; 94(17):1311-9. PubMed ID: 12208896 [TBL] [Abstract][Full Text] [Related]
16. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. Vogel T; Guo NH; Krutzsch HC; Blake DA; Hartman J; Mendelovitz S; Panet A; Roberts DD J Cell Biochem; 1993 Sep; 53(1):74-84. PubMed ID: 8227183 [TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. Zhang W; Swanson R; Xiong Y; Richard B; Olson ST J Biol Chem; 2006 Dec; 281(49):37302-10. PubMed ID: 17040907 [TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis. Hussain S; Slevin M; Matou S; Ahmed N; Choudhary MI; Ranjit R; West D; Gaffney J Angiogenesis; 2008; 11(3):245-56. PubMed ID: 18330714 [TBL] [Abstract][Full Text] [Related]
19. The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain. Li H; Cao W; Chen Z; Acheampong DO; Jin H; Li D; Zhang J; Wang M Biomed Pharmacother; 2013 Sep; 67(7):599-606. PubMed ID: 23906761 [TBL] [Abstract][Full Text] [Related]
20. Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells. Karagiannis ED; Popel AS Int J Biochem Cell Biol; 2007; 39(12):2314-23. PubMed ID: 17707681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]